-

Novanta Hosts ISO event for Humanoid Robot Safety Standards

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced industrial OEMs, announced that it will host an International Organization for Standardization (ISO) working group event for humanoid robot safety standards in Barcelona, Spain, from October 27-30, 2025.

This multi-year ISO initiative aims to define the safety framework guiding how humanoid robots are designed, developed, and deployed around the world. The working group will bring together 40 to 50 international experts and innovators to advance the development of global safety standards for humanoid robots, helping to define safe human/robot interaction in real-world environments. Hosting the ISO event reinforces Novanta’s commitment to collaborative technology innovation in the robotics industry and dedication to advancing safety standards on a global scale.

“Humanoid robotics have their own set of unique challenges, which require a distinctive and dedicated set of safety standards to protect operators, businesses, and the public,” said Chuck Ravetto, Co-Chief Operating Officer of Novanta Inc. “By engaging collaboratively and directly with industry participants through an ISO working group, the industry can collectively develop these safety standards, codifying them under a new international safety standard, ISO 25785-1, to ensure the full range of risks are mitigated. We are honored to be part of their development.”

“We are working with global experts and industry leaders to create guidelines that ensures innovation continues to accelerate, while proper safety measures and standards are developed and incorporated,” added Chuck Ravetto. “We are excited to host this session, to further the industry’s practice of working together, openly, and impartially. The advancement of this physical AI innovation, in a manner that places safety first, will reshape how we work and live.”

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Inc. Media Relations at MediaRelations@novanta.com.

Contacts

Novanta Inc.
Media Relations Contact:
Cari Rutkoskie
MediaRelations@novanta.com

Novanta Inc.

NASDAQ:NOVT

Release Versions

Contacts

Novanta Inc.
Media Relations Contact:
Cari Rutkoskie
MediaRelations@novanta.com

More News From Novanta Inc.

Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical,...

Novanta Inc. Announces $300 Million Private Placement

BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company’s common shares (“Common Shares”) to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an...

Novanta Inc. Announces Acquisition of Riverpoint Medical

BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”), a category leader in high-growth minimally invasive surgical consumables, from Arlington Capital Partners (“Arlington”), a Washington D.C.-area private investment firm. Un...
Back to Newsroom